Pfizer and Progenics are notifying healthcare professionals and patients that the kit presentation of Relistor (methylnaltrexone bromide) subcutaneous injection contains recalled alcohol prep pads from Triad Group. The Relistor vial and other components of the kit are not affected by the defective Triad alcohol pad. Relistor sold in single vials also is unaffected by this recall. Patients using the Relistor kit are advised not to use the Triad alcohol prep pads included in the Relistor packaging for 1 X 7 kits and 1 X 2 starter kits.
Relistor is indicated for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient.